Clinical Trial Update: Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tacrolimus and thymoglobulin as graft-versus-host disease prophylaxis in related donor hematopoietic cell transplantation has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Drugs mentioned

• Prograf (Tacrolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Hematological Malignancies | Phase 2 | Status: COMPLETED | Results posted: 2017-06-01